Edinburgh-based biotechnology company Cytomos has appointed senior life sciences executive Dr Alex Jones as non-executive director, as it looks to accelerate the commercialisation of its cell analysis technology.

Dr Jones brings extensive expertise in life science tools and cell and gene therapy. As the incumbent CEO of Cellply, and previously CEO of Cellular Highways, Dr Jones has a strong track record of building and scaling technology companies, raising growth capital and delivering successful exits. Prior to working in the life science field, Alex spent 10 years as a conservation biologist, primarily in the South Atlantic region.

He joins a three-strong board, led by Executive Chair Alan Raymond.

The new appointment will support Cytomos’ commercial drive for its flagship cell analytic intelligence platform AuraCyt, together with its benchtop technology Celledonia.

The development and manufacture of cell-derived medicines is highly complex and expensive, with a need for solutions to monitor and predict cell parameters in real time. According to Cytomos, using its platform biopharma companies can bring new therapies to market up to six months faster, while cutting costs by enabling critical decisions earlier in development.

The company says early market engagement has been positive. Cytomos has successfully engaged with several strategic partners to integrate its technology into their existing workflows, supported by a dedicated team of scientists and data analysts.